Search

Your selection

Clear all

Filter by content type

Filter by content year

News

Vaxart Hosting Key Opinion Leader Panel Call for Investors

November 16, 2020 - … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by …
News

Vaxart Announces Presentations at the Jefferies Virtual London Healthcare Conference & the Piper Sandler Annual Healthcare Conference

November 16, 2020 - … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by …
News

Vaxart Reports Third Quarter 2020 Financial Results and Provides Business Update

November 12, 2020 - … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by …
News

Vaxart Announces Additional Data from Hamster Challenge Study of its Oral COVID-19 Vaccine

November 12, 2020 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its …
News

Vaxart Announces Positive Hamster Challenge Study Data for its Oral COVID-19 Vaccine

October 14, 2020 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its …
News

Vaxart Announces Dosing First Subject in Phase 1 Clinical Trial of Its Oral Tablet COVID-19 Vaccine

October 13, 2020 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its …
News

Vaxart Announces FDA Clearance of IND Application for Oral COVID-19 Vaccine and Provides Update on COVID-19 Program

September 14, 2020 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its …
News

Vaxart’s Oral COVID-19 Vaccine Candidate Induces Potent Systemic and Mucosal Immune Responses in Preclinical Studies

September 8, 2020 - … rates and eventually eradicating COVID-19 globally.” Study Design The study was designed to assess the relative … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by …
News

Vaxart, Inc. to Participate in September Virtual Investor Conferences

News

Vaxart Appoints Karen J. Wilson to its Board of Directors

Scroll to Top